Skin Cancer | Tumor

Immunotherapy, Other Therapies May Have Improved Overall Survival in Melanoma Brain Metastasis

March 19th 2021, 6:00pm


FDA approval of immunotherapies and BRAF/MEK inhibitors may have impacted overall survival, with a change from seven months between 2010 and 2014 to 13 months between 2015 and 2019.

Indoor Tanning Won’t Cure Seasonal Affective Disorder

March 8th 2021, 1:45pm


As the winter months stretch on, those looking to treat Seasonal Affective Disorder (SAD) may be tempted to use indoor ultraviolet (UV) tanning devices. Not only is indoor tanning a dangerous habit, it does not successfully treat SAD.

What’s Next After Hedgehog Therapy Fails for Basal Cell Carcinoma?

March 1st 2021, 10:00pm


A patient with recurrent basal cell carcinoma discusses his cancer journey, his latest challenge and how he’s now prioritized quality of life over quantity.

In Plain English—Intratumoral Injection: Boosting the immune response against metastatic melanoma by the direct injection of immunotherapy into tumor masses

February 23rd 2021, 2:15pm


Intratumoral injection—the boosting of the immune response against metastatic melanoma by the direct injection of immunotherapy into tumor masses—is a promising treatment method because it’s effective AND it seems to cause fewer toxicities for the patient than combination systemic immunotherapy.

Friendship is Forever

February 16th 2021, 2:00pm


Gina Roller’s best friend, Kerri-Lynn Larimer, adopted and lived by the motto “crazy not to” long before she was diagnosed with metastatic melanoma.

FDA Approves Libtayo, The First Immunotherapy for Advanced Basal Cell Carcinoma

February 9th 2021, 11:00pm


The Food and Drug Administration has granted an accelerated approval to Libtayo for the treatment of patients with advanced basal cell carcinoma, a type of skin cancer, who were previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI was not appropriate.

Why Is the Tissue Bank So Important For Melanoma Research?

February 9th 2021, 2:00pm


We answer this question with the help of Mohammed Kashani-Sabet, M.D., the Director, Center for Melanoma Research and Treatment; and Medical Director, Cancer Center, California Pacific Medical Center.

What is Oral Parity, and Why Does it Matter?

February 2nd 2021, 3:06pm


We answer this question with the help of a pharmacist at a large oncology practice who wishes to remain anonymous.

Avastin Plus Chemotherapy Improves Progression-Free and Overall Survival in Mucosal Melanoma

January 27th 2021, 10:00pm


Avastin, in combination with carboplatin plus paclitaxel (types of chemotherapy), improved progression-free survival and overall survival compared with those who received chemotherapy alone for patients with untreated advanced mucosal melanoma.

Opdivo Plus Yervoy Improves Survival for Patients with Rare Form of Eye Cancer

January 25th 2021, 4:00pm


Combination treatment with Opdivo and Yervoy may have better overall survival rates for patients with metastatic uveal melanoma.